TickerKhojArticles · 9 November 2026
Sahajanand Medical Technologies Reports Record Q2 and H1 FY27 Results
Sahajanand Medical Technologies Limited · Q2 and H1 FY27 · 4 min read
In short
Sahajanand Medical Technologies Limited announced its financial and operational performance for the quarter and half year ended September 30, 2026, delivering record revenue, EBITDA, and PAT alongside improved return ratios and cash conversion metrics.
Record Revenue and Profitability Growth in Q2 and H1 FY27
Quarter two FY 2027 marked a record period for Sahajanand Medical Technologies Limited, featuring the highest-ever revenue, EBITDA, and PAT achieved by the enterprise. Revenue expanded by 24.7% to reach approximately INR373 crores, demonstrating broad-based commercial traction across major operating segments. EBITDA registered an accelerated growth rate of 36.6% to touch INR65 crores, lifting the EBITDA margin from 16% to 17.6% compared to the prior period.
For the first half of fiscal year 2027, total revenue rose by 24.9% to INR725 crores, while EBITDA climbed 43.4% to INR114 crores, yielding a margin of 15.7%. Reported H1 PAT advanced by 7.5% to INR41 crores. The balance sheet reflected total equity around INR745 crores and borrowings of INR300 crores, supported by INR114 crores in cash and liquid investments alongside a net debt to EBITDA multiple of close to 1x.
Strategic Management Guidance and Capital Allocation Initiatives
Management stated clear priorities centered on executing current product launches such as Sironity in India, advancing the TAVI platform, enhancing operating efficiencies, and ramping up utilization at the Telangana manufacturing facility. Leadership outlined a capex guidance of roughly INR70 crores for fiscal years 2027 and 2028, noting that approximately INR44 crores had already been incurred during the first half of fiscal year 2027 for vertical integration, automation, and maintenance.
The executive team projected that ongoing operating leverage and backward integration efforts would support continuous EBITDA margin expansion. Management explicitly guided for an incremental 150 to 200 basis points of EBITDA margin improvement over the next few years, targeting an aggregate EBITDA margin level of approximately 20% by fiscal year 2029.
Editorial Interpretation of Margin Dynamics and Operating Leverage
Modest editorial interpretation indicates that the business successfully converted incremental revenue into higher profitability due to favorable cost discipline. Employee expenses and other overhead costs decreased as a percentage of overall revenue, demonstrating tangible operating leverage. However, gross margins contracted by 170 basis points year-on-year to 74.3% in the first half, primarily driven by faster growth in traded products carrying lower initial margins and shifting regional delivery mixes.
Further editorial review of balance-sheet metrics reveals encouraging improvements in capital efficiency. The cash conversion cycle shortened to 128 days in the first half of fiscal year 2027, down significantly from prior periods. Return on capital employed annualized at 16.7% and return on equity rose to 11.2%, signaling that profits expanded faster than the underlying capital base despite working capital requirements.
Investor Inquiry Resolution and Financial Clarifications
Could management provide specific product-level revenue numbers for IVUS, OCT, or thrombectomy? Unfortunately, since product-level guidance is not provided, the sources do not disclose specific revenue figures for those individual lines. When questioned about the specific quantitative impact of backward integration, the executive team noted that while backward integration will help improve gross margins, they are currently unable to provide a precise numerical guidance figure.
How much of the R&D expense is expensed versus capitalized by the enterprise? Management confirmed that R&D expenditure is treated entirely as a profit-and-loss item with a strict policy against capitalization. Concerning plant capacity metrics, management clarified that certain technical capacities, such as sterilization equipment at the Hyderabad facility, were included in initial regulatory filings but excluded from commercial utilization decks.
Operational Vulnerabilities and Industry Execution Risks
A primary operational risk involves regional regulatory transitions, specifically the ongoing EU MDR certification processes for major legacy product lines like Pipit NC, Pipit SC, Hydra, and Cocoon ahead of the approaching 2027 deadlines. Any delay in securing necessary regulatory approvals could introduce commercial hurdles across key European markets, which currently account for a substantial 36% portion of total company revenues.
Another specific vulnerability stems from input cost pressures and shifting product mixes, as higher input and labor expenses—including ongoing investments into strict quality assurance protocols—partially offset gross profitability. Additionally, reliance on faster-growing traded products creates margin dilution risks that management must continually counterbalance through rigorous SG&A expense control and manufacturing efficiency at newer plants.
Sources
AI-written from the linked primary sources and published automatically under the owner's approved daily policy after deterministic grounding and configured AI claim checks. Not human-reviewed; no recommendation or price target.